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OBJECTIVES: To assess inﬂuence of HRT with the
pulsed oestrogen therapy, on the women’s quality of life
in the early postmenopausal period. METHODS: Quality
of life (QoL) data were derived from the prospective, clin-
ical, open study carried out in the 16 centres in Poland.
The sample consisted of 102 females at the mean age of
52, reporting climacteric symptoms. QoL was assessed 
at the baseline (V-0), after 12 weeks (V-12) and after 16
weeks (V-16) of active treatment. Two instruments were
used: generic Short Form Health Survey (SF-36) and
median-aged women speciﬁc—Women’s Health Ques-
tionnaire (WHQ). The scoring was processed according
to the questionnaire’s manuals. Statistical signiﬁcance 
of the results obtained in comparison with baseline 
were compared using the Wilcoxon signed—rank test.
RESULTS: Mean value of SF-36 Mental Component
Summary (MCS) was 35.2 ± 10.7 at V-0 and 50.4 ± 8.1
at V-16. Mean value of SF-36 Physical Summary Measure
(PCS) was 46.4 ± 7.8 at V-0 and 52.4 ± 5.5 at V-16. Mean
values for the particular dimensions of the WHQ for V-
0 and respectively for V-16 were as follows: depressed
mood; 0.50 ± 0.26 and 0.89 ± 0.16, somatic symptoms;
0.39 ± 0.25 and 0.84 ± 0.21, memory and concentration;
0.35 ± 0.36 and 0.80 ± 0.28, vasomotor symptoms; 0.08
± 0.23 and 0.96 ± 0.17, anxiety and fears; 0.46 ± 0.28
and 0.90 ± 0.2, sexual behaviour; 0.48 ± 0.38 and 0.69
± 0.34, sleep problems; 0.25 ± 0.31 and 0.87 ± 0.25, men-
strual symptoms; 0.68 ± 0.29 and 0.93 ± 0.15, attrac-
tiveness; 0.46 ± 0.53 and 0.62 ± 0.38. Differences
observed in QoL are statistically signiﬁcant with the p <
0.05. CONCLUSIONS: Pulsed oestrogen therapy
achieved by intranasal oestradiol 300mg has a positive
impact on womens’ general QoL and symptoms related
QoL measured in early postmenopausal period. Improve-
ment is expressed in all of the eight SF-36 scales and in
all of the WHQ dimensions.
PWH4
VASOMOTOR SYMPTOMS AND QUALITY OF
LIFE (QOL) IN POSTMENOPAUSAL WOMEN
Bobula JD
Wyeth Research, Collegeville, PA, USA
OBJECTIVES: To measure the impact of vasomotor
symptoms on QoL based on a sample of 1655 healthy,
nonhysterectomized, postmenopausal women aged 40 to
65 who were not on hormonal treatment. METHODS:
QoL was assessed with the Women’s Health Question-
naire (WHQ) and the SF-36. Subgroup analyses were
conducted for women with 1) at least 7 moderate to
severe hot ﬂushes per day as reported on daily diary cards
over a 1-week period; 2) at least one but less than 7 mod-
erate to severe hot ﬂushes per day over the same period;
and 3) no hot ﬂushes. RESULTS: Seven percent (7%) of
study participants were in subgroup 1.64% in subgroup
2, and 29% in subgroup 3. Women in subgroup 1 had
signiﬁcantly worse scores (p < 0.05) than women in sub-
group 3 on 8 of 9 WHQ domains (all but attractiveness)
and 4 of 8 SF-36 subscales (vitality, bodily pain, social
function, and role limitations-emotional) and the mental
composite score. Women in subgroup 1 had signiﬁcantly
worse scores (p < 0.05) than women in subgroup 2 on 5
WHQ domains (vasomotor symptoms, sleep problems,
sexual behavior, somatic symptoms and depressed mood)
and 2 SF-36 subscales (vitality and social function).
Women in subgroup 2 had signiﬁcantly worse scores (p <
0.05) than women in subgroup 3 on 5 WHQ domains
(vasomotor symptoms, sleep problems, somatic symp-
toms, memory/concentration, and menstrual symptoms)
and 2 SF-36 subscales (vitality and role limitations-
emotional) and the mental composite score. For each
intergroup comparison, absolute score differences for the
SF-36 were smaller than those for the WHQ, but always
exceeded at least 4 points out of 100 for statistically sig-
niﬁcant differences. CONCLUSIONS: Women with 
moderate to severe hot ﬂushes experience a signiﬁcant
decrease in quality of life as measured by the WHQ and
SF-36. Wyeth Research supported this project.
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OBJECTIVES: Differences in drug effects on the QOL of
patients undergoing assisted reproductive techniques have
been little. The objective of this study was to perform a
QOL analysis using the Short Form-36 combined with
mathematical modeling to determine whether differences
in QOL exist between patients undergoing COS with fol-
litropin alfa (Gonal-FÒ, Serono) and follitropin beta (Fol-
listimÒ/PuregonÒ liquid, Organon). METHODS: The
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SF-36 questionnaire was administered to patients who
received COS with follitropin alfa (n = 22) or follitropin
beta (n = 21) in a randomized controlled clinical study.
SF-36 scores before and after COS were obtained for each
patient. Results for the eight “dimensions” of the SF-36
were projected using multifactorial analysis to produce a
composite QOL score. Statistical tests were performed to
determine the percentage of relevant information cap-
tured by the multifactorial analysis and hence the quality
of the composite score. The bootstrap technique was used
to generate additional random samples. The Kol-
mogorov–Smirnov test was used to compare the distrib-
utions of the composite scores for the follitropin alfa and
beta groups. RESULTS: The test performed to validate
the composite QOL score gave a value of 0.55 (55% 
of relevant information captured), compared with an
expected score of 0.125 for a random projection of eight
dimensions into one. The distribution of composite scores
for the two groups was signiﬁcantly different after 30 sim-
ulations (p = 0.004), suggesting a difference in the effects
of the two treatments on QOL. A graphical plot of the
results of 5000 simulations showed that the follitropin
beta group had a greater reduction in QOL as a result of
COS compared with the follitropin alfa group. CON-
CLUSIONS: Mathematical modeling conﬁrms a statisti-
cally signiﬁcant difference in QOL effects of the two
r-hFSH preparations in favor of follitropin alfa.
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OBJECTIVE: To develop an instrument to assess male
patient’s and their female partner’s satisfaction with 
the treatment for erectile dysfunction (ED) and assess 
the comprehensiveness, comprehension, acceptability and
clarity of the instrument. METHODS: Four phases were
performed in the questionnaire development; item gener-
ation, face and content validity, cognitive debrieﬁng, cul-
tural and language adaptation. Item generation was based
on literature review, hypothesized characteristics of the
drug and in-depth interviews with patients and their part-
ners. Perceptions and feelings related to the condition 
and their expectations of treatment were examined. Items
were generated simultaneously in English, French, and
German and adapted to each culture. Content and face
validity were assessed by interviews with patients and
partners in 5 countries. Testing of structure and response
scales, cognitive debrieﬁng and veriﬁcation of conceptual
equivalence between languages was assessed. RESULTS:
A total of 55 interviews were conducted to test face and
content validity for patients, partners and experts. The
ﬁnal content areas deemed important included spontane-
ity, quality of erection, quality of ejaculation, sexual plea-
sure, satisfaction with orgasm, conﬁdence, reliability of
treatment, side effect, convenience, overall satisfaction,
conformity to treatment expectations and intentions for
continued use of drug. Cognitive debrieﬁng with patients
and partners found no problems with comprehension.
Results of the debrieﬁng found some words to be prob-
lematic. There were no cultural differences found between
the English, French, or German version. The question-
naire was revised at each phase. The ﬁnal questionnaire
for both the patient and the partner contained 19 ques-
tions. The questionnaire was then translated into 14 
additional languages for use in clinical trials. CONCLU-
SIONS: The TSS is a comprehensive measure of male ED
patients and their respective partners. Further work is
needed to validate the TSS, identify the domains, test the
responsiveness and determine the appropriate scoring.
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Erectile dysfunction has an impact on Health Related
Quality of Life. It can be expected that it also has some
impact on psychological well-being-related variables,
such as self-conﬁdence and self-esteem. It is, therefore,
worthwhile making available in different languages vali-
dated versions of instruments able to measure these 
parameters. OBJECTIVE: To perform the linguistic 
and psychometric validation of a cultural adaptation to
Spanish of the Johnson and McCoy’s Self-Conﬁdence
Scale to be used in patients with erectile dysfunction (ED).
METHODS: After conducting a linguistic validation of
the scale through two forward translations, backward
translation, and cognitive debrieﬁng interviews the ﬁnal
reconciled version of the scale was to be administered to
200 male patients with ED and 200 male subjects without
ED. Participants were screened for ED by general practi-
tioners and further reviewed by urologists. In addition to
the self-conﬁdence scale, all participants were asked to
answer the Rosenberg’s self-esteem scale. RESULTS: A
total of 387 subjects completed the self-conﬁdence ques-
tionnaire. It showed a high internal consistency (Cron-
bach’s alpha = 0.82), similar to the original English
version (Cronbach’s alpha = 0.84). All items showed a
high correlation with the scale. The correlation of the
scale with self-esteem score was adequate (r = 0.60). A
factorial structure of 5 dimensions was observed in the
Spanish version of the self-conﬁdence scale comparable
to the original structure. Self-conﬁdence scores were
